Bladder Cancer ICD-10-CM Codes

What are Bladder Cancer ICD-10-CM Codes?

Bladder cancer is a malignant neoplasm involving abnormal growth of cancer cells in the urinary bladder, particularly its lining. It most commonly originates from urothelial cells (transitional cells), resulting in transitional cell carcinoma, the most common type of bladder cancer. The ICD-10-CM system provides detailed codes that help healthcare professionals document and bill for bladder cancer accurately. Coding by tumor location (such as anterior wall, posterior wall, or bladder dome) enables medical coding teams to ensure precision and compliance.

Below are commonly used and billable ICD-10-CM codes for bladder cancer:

• C67.0 – Malignant neoplasm of trigone of bladder: This code is used when a tumor develops in the trigone, the area between the ureteral openings and the bladder neck. It's essential for identifying malignancies in this triangular region where urine passes from the kidney to the urethra.
• C67.1 – Malignant neoplasm of dome of bladder: This refers to a malignant tumor in the dome of the bladder, which is the uppermost part where the bladder expands to store urine. Coding this site helps distinguish it from overlapping sites or unspecified neoplasm locations.
• C67.2 – Malignant neoplasm of lateral wall of bladder: This code identifies cancer originating in the lateral wall of the bladder, a site commonly affected by urothelial carcinoma. Accurate location coding, such as surgery or radiation therapy, is vital for treatment planning.
• C67.3 – Malignant neoplasm of anterior wall of bladder: Cancers involving the anterior wall are captured under this code. These tumors may affect neighboring urinary organs or present with symptoms like pain, blood inthe  urine, or urinary obstruction.
• C67.4 – Malignant neoplasm of posterior wall of bladder: This code applies to abnormal tissue growth in the posterior wall of the bladder, often detected during diagnostic procedures for hematuria. It helps differentiate from neoplasm of the bladder, unspecified or overlapping lesions.
• C67.5—Malignant neoplasm of bladder neck: This is used when the malignant neoplasm affects the neck of the bladder, the area where urine exits into the urethra. Tumors here can obstruct flow and, depending on diagnosis and risk factors, may require chemotherapy or surgical resection.

Which Bladder Cancer ICD-10-CM Codes are billable?

All the above ICD-10-CM codes are billable and location-specific, ensuring accurate documentation and reimbursement for services such as biopsies, radiation, surgical removal, or chemotherapy.

• C67.0: Yes, billable for the neoplasm in trigone.
• C67.1: Yes, billable for the cancer of the bladder dome.
• C67.2: Yes, billable for the lateral wall malignancy.
• C67.3: Yes, billable for the anterior wall diagnosis.
• C67.4: Yes, billable for the posterior wall involvement.
• C67.5: Yes, billable for the tumor in bladder neck.

Accurate coding is critical for medical billing, diagnosis tracking, and treatment outcomes, especially when the cancer invades other organs or appears as squamous cell carcinoma or adenocarcinoma.

Clinical information

Bladder cancer is a serious disease involving malignant neoplasms in the bladder wall, most often diagnosed as urothelial carcinoma. It can spread to nearby tissues, lymph nodes, or even the kidney and urethra in advanced stages.

Common symptoms

• Blood in urine (hematuria)
• Frequent urination
• Pain during urination
• Lower back pain

Diagnosis methods

• Urine cytology
• Cystoscopy
• CT scans
• MRI
• Biopsy of bladder tissue

Diagnosis must specify the location, type, and stage—such as transitional cell carcinoma, squamous cell carcinoma, or adenocarcinoma—for accurate ICD-10 documentation and tailored treatments.

Risk factors

Several factors increase the likelihood of developing malignant neoplasm of bladder, including:

• Smoking (primary risk factor)
• Exposure to industrial chemicals (e.g., dye, rubber, or leather industries)
• Chronic inflammation of the urinary tract
• Family history of bladder or other urinary tract cancers
• History of radiation therapy to the pelvis

Treatment options

Treatment depends on the tumor stage, histology, and patient health. Common interventions include:

• Surgery (e.g., TURBT or cystectomy)
• Chemotherapy (intravesical or systemic)
• Radiation therapy
• Immunotherapy (e.g., BCG)
• Emerging targeted therapies for urothelial carcinoma

Synonyms include:

• Urothelial carcinoma
• Bladder neoplasm
• Urinary bladder cancer
• Transitional cell carcinoma of the bladder
• Malignant tumor of the urinary bladder
• Unspecified malignant neoplasm of bladder